MedTrace Logo

The Effects of Omega-3 Fatty Acids on Aspirin Resistance

NCT00771914 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2012-11-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if omega-3 fatty acids enhance the antiplatelet effects of aspirin.

Conditions

  • Increased Drug Resistance

Interventions

DRUG

Aspirin

Aspirin 81mg tablet

DRUG

Lovaza

Lovaza 4 grams

DRUG

Both Aspirin and Lovaza

Lovaza 4 grams plus aspirin 81 mg

OTHER

Placebo

Capsule resembling fish oil and a tablet resembling aspirin

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • American College of Clinical Pharmacy

    collaborator OTHER

  • Cornell University

    collaborator OTHER

  • University of Rochester

    lead OTHER

Principal Investigators

  • Robert C Block, MD, MPH · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771914 on ClinicalTrials.gov